B.Riley initiates coverage on Exagen stock with Buy rating, cites diagnostic accuracy

B.Riley initiated coverage on Exagen (NASDAQ:XGN) with a Buy rating and a $15 price target, citing the company's advanced autoimmune diagnostic capabilities, particularly its AVISE CTD product, and a significant operational turnaround projected to drive double-digit revenue growth towards positive free cash flow by Q4 2025. The stock has seen a 217% return over the past year, and while Q2 2025 earnings reported an EPS miss, record revenue of $17.2 million and improved growth visibility have also led Cantor Fitzgerald and KeyBanc to raise price targets and upgrade ratings, signaling a broadly positive analyst sentiment for the company.

Analysis

Analyst sentiment for Exagen (NASDAQ:XGN) has turned decidedly positive following an initiation of coverage by B.Riley with a Buy rating and a $15.00 price target. This bullish outlook is underpinned by the company's operational turnaround since 2022, which has included a 75% reduction in cash burn and improved reimbursement rates, positioning the company for projected positive free cash flow and adjusted EBITDA by Q4 2025. The core investment thesis centers on Exagen's superior diagnostic technology, with its AVISE CTD product identifying approximately 80% of lupus patients versus less than 45% for conventional tests. This technological edge is expected to continue with a new rheumatoid arthritis test, slated for launch by early 2026, projected to have an 85% identification rate. The company's recent Q2 2025 results support the growth narrative, delivering a record quarterly revenue of $17.2 million, though this was tempered by an earnings per share loss of $0.21, which missed the anticipated $0.15 loss. Despite the EPS miss, the strong revenue performance and improved growth visibility have prompted other firms, including Cantor Fitzgerald and KeyBanc, to raise their price targets to $10.00 and $12.00, respectively. B.Riley justifies its premium valuation—a 4.0x enterprise value to 2025 sales multiple—by citing Exagen's above-average projected revenue growth of 22% for 2025, which outpaces the peer average of 17%.

Key Decisions for Investors

• Given the strong analyst consensus, superior diagnostic technology, and a clear path to profitability, investors may view the stock favorably despite its recent 217% year-over-year gain, as multiple price targets suggest further potential upside.
• It is critical to monitor execution against management's guidance, particularly the achievement of double-digit revenue growth and the key milestone of positive free cash flow and adjusted EBITDA by Q4 2025.
• While top-line growth is robust, the recent EPS miss highlights a risk in profitability execution, so investors should scrutinize future earnings for progress in narrowing losses alongside continued revenue momentum.
• The successful development and launch of the advanced rheumatoid arthritis biomarkers by the 2026 target is a key long-term catalyst that warrants close observation to validate the company's innovation pipeline and future growth trajectory.